The difference was even wider among the patients with VUS variants: 71% (57/80) had only non-VHL component tumors, 23% (18/80) had no tumors, and 5% (4/80) and 1% (1/80) had isolated RCC and isolated paraganglioma, respectively. This evidence concerns the gene VHL and paraganglioma.